Omics Approaches in Breast Cancer
53,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
27 °P sammeln
  • Broschiertes Buch

Breast cancer is the most common cancer in females that accounts for highest cancer specific deaths worldwide. In the last few decades research has proven that breast cancer can be treated if diagnosed at early stages and proper therapeutic strategy is adopted. Omics-based recent approaches have unveiled the molecular mechanism behind the breast tumorigenesis and aid in identification of next-generation molecular markers for early diagnosis, prognosis and even the effective targeted therapy. Significant development has taken place in the field of omics in breast cancer in the last decade. The…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Breast cancer is the most common cancer in females that accounts for highest cancer specific deaths worldwide. In the last few decades research has proven that breast cancer can be treated if diagnosed at early stages and proper therapeutic strategy is adopted. Omics-based recent approaches have unveiled the molecular mechanism behind the breast tumorigenesis and aid in identification of next-generation molecular markers for early diagnosis, prognosis and even the effective targeted therapy. Significant development has taken place in the field of omics in breast cancer in the last decade. The most promising omics approaches and their outcomes in breast cancer have been presented in this book for the first time. The book covers omics technologies and budding fields such as breast cancer miRNA, lipidomics, epigenomics, proteomics, nutrigenomics, stem cell, pharmacogenomics and personalized medicine and many more along with conventional topics such as breast cancer management etc. It is a research-based reference book useful for clinician-scientists, researchers, geneticists and health care industries involved in various aspects of breast cancer. The book will also be useful for students of biomedicine, pathology and pharmacy.
Autorenporträt
Dr Debmalya Barh is the founder of Institute of Integrative Omics and Applied Biotechnology (IIOAB) at Nonakuri, Tamluk, West Bengal, India. His core competencies include bioinformatics, genome, genomics and proteomics, cell signaling, integrative omics based marker and target discovery, cancer pharmacogenomics, personalized medicine, cardiovascular and infectious diseases. He has been a consultant for three top healthcare and diagnostic companies in USA. He is the reviewer/editorial board member of many journals like CMAJ, Molecular Medicine, Bioinformatics, BMC Genomics, BMC Systems Biology, Journal of Medical Informatics, Current Oncology, Gene Therapy, J. Cardiovascular Dis Res, J Integrated Omics, AIOAB. He has several scientific publications including genome sequences, journal articles, book chapters and reference books.
Rezensionen
From the book reviews:

"This will be valuable for those who are interested in learning about various 'omics' approaches, findings in breast cancers through bioinformatics studies, and technical considerations of breast cancer diagnosis and treatment. ... this book is well structured and contains an abundance of published findings. The area of 'omics' is essential to breast cancer research, and this book nicely summarizes and presents up-to-date findings." (Shiuan Chen, Doody's Book Reviews, March, 2015)